News

Priority Review is granted to products that would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious disease. The

The trial is being conducted in conjunction with the TIMI Study Group at Harvard Medical School and Brigham and Women's Hospital. The phase III study is designed to

Currently, there are no marketed therapies specifically indicated for prevention of re-infection post-liver transplant in HCV-positive patients. Nabi Biopharmaceuticals is co-developing Civacir with Italian biopharmaceutical company Kedrion. Kedrion

Under the terms of the agreement, BG Medicine will integrate life science technology from Applied Biosystems into its proteomic and metabolomic systems pharmacology workflows and begin to explore

Aradigm previously received orphan drug designation for the same formulation of ciprofloxacin for the management of cystic fibrosis in April 2006. Aradigm's liposomal ciprofloxacin is an aerosolized formulation

Neupro has been available in the European market since March 2006 for the treatment of early stage idiopathic Parkinson's disease as a monotherapy. The drug has already been

Pharming believes that although the number of transplantations is currently relatively small, DGF is an important medical need providing a significant market opportunity. Transplantation procedures are costly and

Bicifadine is a serotonin and norepinephrine reuptake inhibitor (SNRI). Compared to the currently approved SNRI's, Bicifadine has a unique ratio of serotonin versus norepinephrine reuptake inhibition, which is

MER 103 is an enteric-coated tablet of Fosamax and GIPET, Merrion’s platform technology which increases drug absorption. The study confirmed several important improvements for patient convenience and compliance